Antibodies elicited by the 2025-2026 influenza vaccine in humans
Liu, J.; Li, S. H.; Ye, N.; Griffiths, T.; Drapeau, E. M.; Atkinson, R.; Collman, R.; Hensley, S.
Show abstract
A new H3N2 variant (named subclade K) possesses several key hemagglutinin substitutions and is circulating widely during the 2025-2026 influenza season. In this report, we completed experiments to determine if the 2025-2026 seasonal influenza vaccine elicits antibodies in humans that recognize this variant. We find that H3N2 subclade K viruses are antigenically advanced; however, the 2025-2026 seasonal influenza vaccine elicited antibodies in many individuals that efficiently recognized these viruses. Thus, the current seasonal influenza vaccine will likely be somewhat effective at preventing H3N2 subclade K virus infections.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
- Neutralization of spike 69/70 deletion, E484K, and N501Y SARS-CoV-2 by BNT162b2 vaccine-elicited sera 95%
- Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals 94%
- Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster 94%
Similar papers in this journal
- SARS-CoV-2 Omicron spike mediated immune escape, infectivity and cell-cell fusion 94%
- A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures 93%
- SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.